Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection [NA]
Clinical trial assessing neuroinflammation and neurocognitive function in patients with acute hepatitis C and chronic HIV co-infection; stat…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
A completed real-world evidence study evaluating the effectiveness of paritaprevir/ombitasvir ± dasabuvir ± ribavirin with patient support i…
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis [Phase 2]
Phase 2 study evaluating simtuzumab in adults with liver fibrosis and hepatitis C, including HIV co-infection; study completed with results …
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis [Phase 2]
Phase 2 trial evaluating sofobuvir/velpatasvir with ribavirin for 12 weeks in chronic HCV with Child-Pugh C cirrhosis; results posted in 201…
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: Brief Intervention for Rural Women at High Risk for HIV/HCV [NA]
A completed clinical trial evaluating a brief intervention for rural women at high risk for HIV/HCV; results have been posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
Observational real-world study assessing the effectiveness of Paritaprevir/ritonavir-ombitasvir +/- dasabuvir +/- ribavirin in adults with c…
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients [Phase 2]
Phase 2 trial update of Seraprevir combined with Sofosbuvir in adults with chronic Hepatitis C Virus infection (genotypes 2, 3, and 6).
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir [Phase 4]
A Phase 4 clinical trial completed evaluating sofosbuvir and daclatasvir for treating hepatitis C in patients with chronic renal failure.
-
FDA approval · 2019-09-27FDA Approved: VOSEVI — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) from Gilead Sciences, Inc. VOSEVI is a fi…
-
FDA label_change · 2019-09-26FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie. The action updates the product labeling to r…
-
CLINICAL_TRIALS trial_result · 2019-09-25Clinical Trial Update: Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C [NA]
Completed trial of a web-based intervention to reduce alcohol use in veterans with hepatitis C; results posted in 2019.
-
FDA approval · 2019-09-19FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
The FDA approved a supplemental application for Ledipasvir and Sofosbuvir submitted by Asegua Therapeutics LLC, resulting in an approved mod…
-
FDA approval · 2019-09-19FDA Approved: SOVALDI — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Sovaldi (sofosbuvir) from Gilead Sciences, Inc., updating the drug's labeling.
-
FDA approval · 2019-09-19FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) submitted by Gilead Sciences, Inc. The approval updates the lab…
-
FDA approval · 2019-09-19FDA Approved: HARVONI — Supplemental Application (Gilead Sciences, Inc)
The FDA approved a supplemental application for HARVONI (ledipasvir/sofosbuvir) from Gilead Sciences.
-
CLINICAL_TRIALS research · 2019-09-18Clinical Trial Update: Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia
A completed real-world study evaluating the effectiveness of paritaprevir/ritonavir-ombitasvir +/- dasabuvir +/- ribavirin in chronic hepati…
-
CLINICAL_TRIALS trial_result · 2019-09-16Clinical Trial Update: The Patient-Reported Outcomes Project of HCV-TARGET
Clinical trial update reporting patient-reported outcomes for the HCV-TARGET project, completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
A completed clinical trial evaluating the impact of an alternative Hepatitis C screening method on linkage-to-care among people who inject d…
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients [Phase 3]
Phase 3 clinical trial update evaluating the effects of a direct-acting antiviral in chronic hepatitis C patients.
-
CLINICAL_TRIALS trial_result · 2019-09-11Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive [Phase 2]
Phase 2 study evaluating AL-335 with odalasvir and simeprevir for chronic hepatitis C genotypes 1 or 2 in Japanese patients; completed with …
-
CLINICAL_TRIALS trial_result · 2019-09-11Clinical Trial Update: Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) [Phase 4]
Phase 4 trial update focused on simplifying pangenotypic HCV treatment and retreatment strategies in Rwanda and similar settings.
-
CLINICAL_TRIALS trial_result · 2019-09-11Clinical Trial Update: Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment [Phase 4]
A Phase 4 clinical trial on post-transplant Epclusa (sofosbuvir/velpatasvir) treatment in patients with chronic hepatitis C after lung trans…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS [NA]
A completed CHAMPS study investigating chronic hepatitis C management to improve outcomes, with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-09-04Clinical Trial Update: Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 [Phase 3]
Phase 3 trial evaluating 8 weeks of Glecaprevir/Pibrentasvir in treatment-naïve adults with HCV Genotype 1-6 and APRI ≤1; results posted aft…
-
EMA withdrawal · 2019-08-30EMA Expired: Daklinza (daclatasvir dihydrochloride) — Bristol-Myers Squibb Pharma EEIG
EMA indicates that Daklinza (daclatasvir dihydrochloride) has expired status as a medicinal product for chronic hepatitis C in the EU.